P2.10. ORA-LM: Molecular Analysis in Cerebrospinal Fluid of ALK or EGFR Positive NSCLC Patients with Leptomeningeal Metastases - PDF(Abstract)
Back to course
Pdf Summary
Asset Subtitle
Tijmen van der Wel
Meta Tag
Speaker Tijmen van der Wel
Topic Metastatic NSCLC: Targeted Therapy - FUSIONS
leptomeningeal metastases
non-small cell lung cancer
ALK mutation
EGFR mutation
cerebrospinal fluid analysis
resistance mechanisms
targeted therapy
osimertinib dose escalation
Powered By